ArticleOphthalmology and eye diseases2013
Voclosporin as a treatment for noninfectious uveitis.
Article in Ophthalmology and eye diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 15 citations in OpenAlex.
- Recent advances in immunotherapies for lupus nephritis.Pediatric nephrology (Berlin, Germany) · 2023Review
- Cyclic peptide drugs approved in the last two decades (2001-2021).RSC chemical biology · 2022Review
- Calcineurin Inhibitor Voclosporin Preserves Corneal Barrier and Conjunctival Goblet Cells in Experimental Dry Eye.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2020Article
- Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease.Pharmaceutical research · 2019Review
- Emerging therapies for noninfectious uveitis: what may be coming to the clinics.Journal of ophthalmology · 2014Review
- Pharmacotherapy for uveitis: current management and emerging therapy.Clinical ophthalmology (Auckland, N.Z.) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Voclosporin is a relatively new calcineurin inhibitor that has been used successfully in humans for the treatment of plaque psoriasis. Available data indicate a good safety profile for this treatment and a significant increase in quality of life for psoriasis patients. More recently, voclosporin has been used to treat ophthalmic conditions such as uveitis. The limited data available indicate at least comparable results relative to current therapy with a better safety profile. Here, we analyze data from human and animal studies and the mode of action of voclosporin. Available safety profile data are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.